Eperisone Hydrochloride Tablets

Eperisone hydrochloride is a central skeletal muscle relaxant with multiple pharmacological effects. Animal experiments show that eperisone can dose-dependently inhibit the decerebrate rigidity (gamma;-rigidity) and ischemic decerebrate rigidity (alpha;-rigidity) caused by thalamic transection in rats, inhibit the monosynaptic and polysynaptic reflex potentials caused by stimulation of the dorsal roots of the spinal cord in cats with spinal cord injury, and may reduce the sensitivity of muscle spindles by inhibiting the gamma;-neuron system. Eperisone has the effects of calcium antagonists and blocking muscle sympathetic nerves, acting on vascular smooth muscle, dilating blood vessels, and increasing blood flow. Animal experiments have found that spinal cord perfusion of eperisone in rats can inhibit the pain reflex caused by tail pinch pain, while the pain reflex will recover when the perfusion is stopped, indicating that it has an analgesic effect at the spinal cord level. Patients with spastic paralysis who have stroke take eperisone hydrochloride, which can improve the Cybex torque curve and myograph, and facilitate voluntary movements, such as extension and flexion of the limbs, but will not reduce muscle strength. Toxicological study, repeated dose toxicity: Beagle dogs were orally administered 10, 25 and 62.5 mg/kg of eperisone hydrochloride for 53 consecutive weeks. At doses of 25 mg/kg and above, animals showed vomiting, salivation, tonic-clonic convulsions, abnormal gait, weakness, reduced weight and diet, decreased body temperature, increased water consumption, hematuria and decreased spontaneous movement. Animals in the 62.5 mg/kg group showed slow heart rate and prolonged QT interval. Pathological examination revealed an increase in absolute and relative liver weight, mild edema and necrosis of hepatocytes, thickening of the renal wall and narrowing of the lumen. The maximum non-toxic dose is 10 mg/kg (calculated in mg/m2, approximately equivalent to 0.72 times the recommended daily dose for human clinical use). Genetic toxicity: The Ames test result of eperisone hydrochloride was negative. Reproductive toxicity: General reproductive toxicity test: SD rats were orally administered 50, 100 and 200 mg/kg of eperisone hydrochloride, and no abnormalities were observed. Teratogenic sensitive period toxicity test: pregnant rats were orally administered with 25, 50, 100, 200 and 500 mg/kg of eperisone hydrochloride. Animals in the 200 mg/kg and above dose groups showed liver and kidney damage in maternal rats; maternal rats in the 500 mg/kg group died, general behavior changed, and body weight and water consumption decreased; doses of 200 mg/kg and below had no effect on maternal rat weight, production and lactation. Fetal development was delayed in the 500 mg/kg group, and no fetal lethality or teratogenic effects were observed. Perinatal toxicity test: pregnant rats were orally administered with 50, 100 and 200 mg/kg of eperisone hydrochloride. Animals in the 200 mg/kg dose group showed a slight increase in stillbirth rate, increased serum cholesterol levels in maternal rats, and turbidity in liver and kidney cells. The weight growth of young rats was inhibited and patellar ossification was delayed. Dependence: Monkey dependence tests did not show physiological and mental dependence on eperisone hydrochloride.

Each tablet of Yi Yu contains 50 mg of ethylphenidate hydrochloride.

This product is a light orange-white sugar-coated tablet, which appears white after removing the sugar coating.

Suitable for neck-shoulder-arm syndrome, periarthritis of shoulder, lower back pain and waist-leg pain, etc.

Generally, adults take 1 tablet (50 mg of eperisone hydrochloride) 3 times a day, orally after meals. The dosage can be increased or decreased depending on age and symptoms.

1. The medication should be discontinued when the following adverse reactions occur: shock, abnormal liver function, abnormal kidney function, abnormal blood test (including red blood cell count, hemoglobin value); 2. The following adverse reactions may occur: Skin: rash, itching, etc.; Mental and nervous system: insomnia, headache, drowsiness, body stiffness, numbness of limbs, decreased perception, tremor of limbs, etc.; Digestive system: nausea, vomiting, loss of appetite, stomach discomfort, dry mouth, constipation, diarrhea, abdominal pain, abdominal distension, etc., occasionally stomatitis; Urinary system: urinary retention, urinary incontinence, feeling of incomplete urination, etc.; Systemic symptoms: weakness in limbs, unstable standing, general fatigue, occasionally dizziness, decreased muscle tension, etc.; Others: facial heat, sweating, etc.

Patients with a history of allergy to any ingredient in this product are contraindicated.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. Use with caution in pregnant women. 2. Forbidden to use in lactating women. Precautions for the elderly: Not yet clear.

There have been reports of ocular accommodation disorders when a similar drug, tolperisone hydrochloride, is used in combination with methoxycarbamol.

Keep tightly closed in a cool and dry place.

50 mg

Tentative 36 months

Hunan Yada Pharmaceutical Co., Ltd.

• Founded in:

  1998-12-08

• Address:

  No. 85, Yada Road, Furong District, Changsha

• Tax NO.:

  914301007121046769

• Registered Funds:

  25.42 million yuan

• Website:

  Log in to view

• Email:

  Log in to view